A paired-agent fluorescent molecular imaging strategy for quantifying antibody drug target engagement in in vivo window chamber xenograft models.

Autor:	Kayaalp Nalbant E; Biomedical Engineering, Illinois Institute of Technology, Chicago, IL.; Authors contributed equally., Rounds C; Biomedical Engineering, Illinois Institute of Technology, Chicago, IL.; Authors contributed equally., Sadeghipour N; Molecular Imaging Program at Stanford, Stanford University, Stanford, CA., Meng B; Thayer School of Engineering, Dartmouth College, Hanover, NH., Folaron MR; Thayer School of Engineering, Dartmouth College, Hanover, NH., Haldar C; Thayer School of Engineering, Dartmouth College, Hanover, NH., Strawbridge RR; Thayer School of Engineering, Dartmouth College, Hanover, NH., Samkoe KS; Thayer School of Engineering, Dartmouth College, Hanover, NH., Davis SC; Thayer School of Engineering, Dartmouth College, Hanover, NH., Tichauer KM; Biomedical Engineering, Illinois Institute of Technology, Chicago, IL.
Jazyk:	angličtina
Zdroj:	Proceedings of SPIE--the International Society for Optical Engineering [Proc SPIE Int Soc Opt Eng] 2020 Feb; Vol. 11219. Date of Electronic Publication: 2020 Feb 19.
DOI:	10.1117/12.2545182
Abstrakt:	A paired-agent fluorescent molecular imaging strategy is presented as a method to measure drug target engagement in whole tumor imaging. The protocol involves dynamic imaging of a pair of targeted and control imaging agents prior to and following antibody therapy. Simulations demonstrated that antibody "drug target engagement" can be estimated within a 15%-error over a wide range of tumor physiology (blood flow, vascular permeability, target density) and antibody characteristics (affinity, binding rates). Experimental results demonstrated the first in vivo detection of binding site barrier, highlighting the potential for this methodology to provide novel insights in drug distribution/binding imaging.
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu